Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Vandetanib Combined With Capecitabine, Oxaliplatin and Bevacizumab for the First-Line Treatment of Metastatic Colorectal Cancer

NCT00532909 is registered in ClinicalTrials.gov with Branimir Sikic as lead sponsor.

NCT NCT00532909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00532909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Vandetanib Combined With Capecitabine, Oxaliplatin and Bevacizumab for the First-Line Treatment of Metastatic Colorectal Cancer
Lead sponsor
Branimir Sikic
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2006
Completion date
May 31, 2010
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal, colon, and rectal cancers, colon/rectal cancer, colorectal neoplasms